STERIS - STE Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STE shares.
View STE analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1 year target prices for STERIS's stock. Their STE share price forecasts range from $237.00 to $275.00. On average, they predict the company's stock price to reach $252.00 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for STE or view top-rated stocks among Wall Street analysts.

STERIS's stock was trading at $243.41 at the beginning of the year. Since then, STE stock has decreased by 34.0% and is now trading at $160.72.
View the best growth stocks for 2022 here.

STERIS saw a increase in short interest in the month of August. As of August 15th, there was short interest totaling 1,890,000 shares, an increase of 31.3% from the July 31st total of 1,440,000 shares. Based on an average daily volume of 478,100 shares, the days-to-cover ratio is currently 4.0 days. Currently, 1.9% of the shares of the company are sold short.
View STERIS's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our STE earnings forecast.

STERIS plc (NYSE:STE) announced its earnings results on Tuesday, November, 2nd. The medical equipment provider reported $1.99 EPS for the quarter, beating analysts' consensus estimates of $1.82 by $0.17. The medical equipment provider had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.16 billion. STERIS had a trailing twelve-month return on equity of 12.40% and a net margin of 7.90%. During the same period last year, the company posted $1.48 earnings per share.
Read the conference call transcript.

STERIS declared a quarterly dividend on Thursday, July 28th. Shareholders of record on Wednesday, September 7th will be paid a dividend of $0.47 per share on Friday, September 23rd. This represents a $1.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Tuesday, September 6th. This is a boost from the stock's previous quarterly dividend of $0.43.
Read our dividend analysis for STE.

STERIS (NYSE:STE) pays an annual dividend of $1.88 per share and currently has a dividend yield of 1.15%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 50.40%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STE will have a dividend payout ratio of 19.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for STE.

STERIS issued an update on its FY 2023 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $8.40-$8.60 for the period, compared to the consensus estimate of $8.70. The company issued revenue guidance of $5.00 billion-$5.00 billion, compared to the consensus revenue estimate of $5.12 billion.

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

STERIS's stock is owned by many different retail and institutional investors. Top institutional investors include WCM Investment Management LLC (6.10%), Massachusetts Financial Services Co. MA (4.60%), State Street Corp (4.24%), Price T Rowe Associates Inc. MD (2.39%), Pictet Asset Management SA (1.69%) and Northern Trust Corp (1.31%). Insiders that own company stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves and Walter M Rosebrough Jr.
View institutional ownership trends.

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STE stock can currently be purchased for approximately $160.72.

STERIS (NYSE:STE) has a market capitalization of $16.07 billion and generates $4.59 billion in revenue each year. The medical equipment provider earns $243.89 million in net income (profit) each year or $3.73 on an earnings per share basis.

The company employs 16,422 workers across the globe.

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The official website for the company is www.steris.com. The medical equipment provider can be reached via phone at (531) 232-2000, via email at julie_winter@steris.com, or via fax at 440-639-4457.